New pill targets rare cancer mutation in early trial
NCT ID NCT06386146
First seen Jan 28, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at least one other cancer treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGDenver, Colorado, 80218, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
RECRUITINGBeijing, Beijing Municipality, 100000, China
-
Research Site
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Research Site
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Research Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Research Site
RECRUITINGZhengzhou, Henan, 451191, China
-
Research Site
RECRUITINGShenyang, Liaoning, 110801, China
-
Research Site
RECRUITINGJinan, Shandong, 250117, China
-
Research Site
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Research site
TERMINATEDLake Mary, Florida, 32771, United States
-
Research site
RECRUITINGSt Louis, Missouri, 63110, United States
-
Research site
TERMINATEDCanton, Ohio, 44718, United States
-
Research site
RECRUITINGCleveland, Ohio, 44195, United States
-
Research site
RECRUITINGHouston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAB-30355 (oral drug targeting TP53 Y220C mutation)
What this could lead to
If successful, this could lead to a new targeted treatment option for people with advanced solid tumors that have a specific TP53 mutation.
What could go wrong
This is an early-phase trial (Phase 1/2a) with only 144 participants, so safety and effectiveness are not yet proven. The drug may not shrink tumors or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.